Introduction
T cell activation requires at least two distinct signals. One signal is antigen (Ag) specific and is derived from the major histocompatibility complex (MHC)/Ag peptide complex on the antigen presenting cell (APC) via T cell receptor (TCR). The second signal is received from interaction with accessory or costimulatory molecules. The interaction between CD28 on T lymphocytes and CD80 (B7-1) or CD86 (B7-2) on APC provides the necessary second signal to overcome the anergic state. CTLA-4 is a CD28 homologue that is inducibly expressed after T cell activation, interacts with CD80 or CD86, and delivers a negative signal that terminates immune responses. 1, 2 CD80 is not expressed on resting monocytes and only minimally on dendritic cells. Although expression can be induced on activated macrophages, B cells and NK cells, the time course of CD80 induction is slower than that of 
CD86
. 3 In contrast, CD86 is expressed constitutively on resting monocytes and can be rapidly induced on activated B cells, 4 and has faster dissociation kinetics than CD80. 5 In addition, CD80 was shown to be expressed in vivo on T cells infiltrated in skin lesions of psoriasis and mycosis fungoides, 6 rheumatoid synovial T cells 7 and peripheral blood T cells from patients with systemic lupus erythematosus (SLE). 8 Expression of CD80 on peripheral blood CD4 + T cells has been shown to be upregulated in patients with active multiple sclerosis (MS). 9 Furthermore, B7 blockage using anti-B7 antibodies or CTLA-4Ig can prevent the development of murine experimental autoimmune encephalomyelitis (EAE), a T cellmediated autoimmune disease that shares many clinical and histological features with human MS. [10] [11] [12] [13] It was considered possible that structural variations as well as the dysregulation in the expression of the costimulatory molecules may be associated with susceptibility to autoimmune or chronic inflammatory diseases. It was reported that polymorphism within CTLA-4 exon 1 (49A/G) and that of the dinucleotide repeats within 3′-untranslated region (3′-UTR) seemed to be significantly associated with insulin-dependent diabetes mellitus (IDDM), 14, 15 Graves' disease 16, 17 or Hashimoto's thyroiditis. 18 Moreover, a genome-wide linkage study reported 2q33 and 3q13 as candidate chromosomal regions for rheumatoid arthritis (RA), which are adjacent to the loci where CD28 and CTLA-4, CD80 and CD86 are localized, respectively. 19, 20 We have been trying to detect susceptibility genes to human rheumatic or autoimmune diseases through extensive polymorphism screening of the candidate genes. [21] [22] [23] [24] [25] [26] Based on the functional importance and chromosomal locations, genes coding for the costimulatory molecules were considered as strong candidates for the susceptibility gene to rheumatic diseases. We recently reported that CTLA-4 exon 1 polymorphism does not substantially contribute to the susceptibility to RA and SLE in Japanese. 27 Thus far, no systematic screening for the polymorphisms of CD28, CD80 and CD86 genes has been reported. In the present study, we performed polymorphism screening of the coding regions of these genes, as well as the promoter region of CD80, to test the possible role of there genes in the pathogenesis of RA and SLE, using the case-control association analysis.
Results
Screening for the polymorphisms of CD80, CD86 and CD28 coding regions The entire coding regions of CD80 and CD86 were screened for polymorphisms using PCR-preferential homoduplex formation assay (PHFA) in 101 patients with RA, 57 patients with SLE and 168 healthy individuals. Variations were detected within exon 3, exon 4 and intron 5 of CD80, and exon 8 of CD86. Sequencing analysis revealed that each of these variations derived from a single nucleotide substitution. Among these variations, CD80 864 (A→G) and CD86 1057 (G→A) were nonsynonymous, resulting in CD80 N186D and CD86 A304T amino acid substitutions, respectively (Table 1 ). Allele carrier rates of each substitution in healthy individuals and patients are shown in Table 2 . Variations at CD80 position 452 and CD86 position 1057 were present in a substantial proportions of the subjects, and were considered as single nucleotide polymorphisms within the coding sequences (cSNPs). Genotyping for these two cSNPs was performed using PCR-single strand conformation polymorphism (SSCP), and the results are shown in Table 3 . Significant association with the susceptibility to RA or SLE was not observed. The amino acid positions were counted from the translation initiation sites. The haplotypes formed by SNPs within the promoter and 5′-UTR are designated prom 1-4 in the order of allele frequencies in healthy Japanese individuals (Table 4) . Since CD80 and CD86 were mapped to the same chromosomal region, the presence or absence of linkage disequilibrium was estimated using the typing results of CD80 452G/A and CD86 1057G/A by a computer program based on the maximum likelihood method. 28 Significant linkage disequilibrium was not detected between these cSNPs (data not shown).
Genes and Immunity
In the screening of CD28 gene, no variation was found in the coding region in 30 samples, suggesting that there are no cSNPs in CD28.
Screening for the polymorphisms in CD80 5′-flanking region using direct sequencing Polymorphisms of the 5′-flanking region of CD80 gene were screened by direct sequencing of the genomic DNAs from 10 patients with RA, 10 patients with SLE and 10 healthy individuals. Five SNPs in the promoter region, −454 C/A, −387 T/C, −232 G/A, −79 C/G and −7 T/C, as well as one in 5′-UTR, +5 C/A, were identified. In addition, 11 subjects were found to have five base insertion, CATGA, at position −558. Interestingly, all individuals possessing −558ins (CATGA) had −454A, −232A, −7C and +5A, suggesting that these variations are carried by a single allele. 
Genotyping of SNPs within the 5′-flanking region of CD80
The 5′-flanking region of CD80 gene were separated in two fragments of the appropriate size, −521 ෂ −350 (171 bp) and −136 ෂ +43 (179 bp), for the genotyping. Genotyping of the upstream fragment was successfully performed using PCR-SSCP ( Figure 1 ). However, since the distinction of downstream alleles was not successful with various SSCP conditions, genotyping system was developed using PCR-PHFA.
In the upstream fragment encompassing two SNPs, −454 C/A and −387 T/C, only three patterns were observed in the PCR-SSCP analysis (Figure 1 ). Sequencing analysis indicated that these variations are present as three allelic combinations; C −454 -T −387 , C −454 -C −387 and A −454 -T −387 . Similarly, PCR-PHFA analysis revealed that the three SNPs of the downstream region are present as three alleles: C −79 -T −7 -C 5 , G −79 -T −7 -C 5 and C −79 -C −7 -A 5 . By combining these upstream and downstream fragment genotypes, it was deduced that CD80 promoter variations are present as four allelic combinations. We tentatively designated these alleles as prom 1-4, in the order of allele frequency in the controls (Table 1) . Table 4 shows the allele and genotype frequencies of the deduced CD80 5′-flanking region alleles. No significant association of CD80 promoter alleles with RA or SLE was observed. 
Analysis on the association with clinical characteristics of SLE
The patients with SLE were stratified according to the presence or absence of clinical and immunological characteristics, and the association with the detected variations was examined. As shown in Table 5 , significant association was observed between the CD86 position 1057 SNP and anti-Sm antibody. Thus, patients heterozygous for CD86 1057G coding for Ala at amino acid position 304 were more likely to have anti-Sm antibody. No association was observed for CD80 promoter alleles (data not shown). Because this association study was carried out in a retrospective manner, association with the severity of RA was not analyzed. In addition, association was not detectable when the patients with RA and controls were compared after stratification by CTLA-4 or HLA-DRB1 genotypes (data not shown).
Discussion
In the present study, several new polymorphisms were identified in the 5′ flanking and coding regions of CD80 and CD86. Two of them encode amino acid substitutions, CD80 N186D and CD86 A304T. CD80 position 186N is conserved between human and mouse, 29, 30 while CD86 position 304 is not, 31, 32 which may be related to the difference in the allele frequency of these two cSNPs observed in this study. CD80 N186D introduces a charge change and disrupts one of the potential glycosylation sites in the C-like extracellular domain. Although a number of studies have been carried out using the site-directed mutagenesis, the binding sites of CD28/CTLA-4 on CD80/CD86 have not been established. It was reported that both extracellular immunoglobulin-like domains of CD80 are necessary to interact with CD28 and CTLA-4. 33, 34 On the other hand, a splice variant has been identified in mice which lacks the C-like domain but still is capable of binding to CD28Ig, suggesting that the C-like domain is not essential for CD28-binding.
35 CD86 A304T introduces a potential phosphorylation site in the cytoplasmic region; however, no information is available whether this substitution may influence the signal transduction pathway. Therefore, it is not clear at present whether the amino acid substitutions of CD80 and CD86 detected in this study have a substantial effect on the function of these molecules.
Although CD80 and CD86 are both mapped to 3p21, 36 significant linkage disequilibrium was not observed between CD80 position 452 and CD86 position 1052. The precise physical or genetic distance between these two loci is, to our knowledge, not known. In spite of the crucial role of CD28 for T cell activation, CD28-deficient mice were shown to have normal T cell development and normal cell-mediated immunity, although T cell-mediated humoral immunity was significantly reduced. 37 The amino acid identity between human and murine CD28 is 68%, 38 which is not significantly higher than that of CD80 (60%) 29 and CD86 (50%). 31 It is therefore surprising that no variation was identified in human CD28. It may suggest the indispensable role of CD28 in humans. Alternatively, the absence of not only nonsynonymous, but also of synonymous substitutions may suggest the low mutation rate at this locus. Recently, a new costimulatory molecule related to CD28, inducible co-stimulator (ICOS), was identified in human. 39 It was proposed that ICOS binds to receptor(s) on B cells other than CD80 and CD86, and may provide the dominant signal for T cells in the later phase of T cell-B cell cooperation in the lymphoid system. In CD28-deficient mice, homologue of ICOS and its counter-receptor may partly substitute the role of CD28 in the T cell costimulation. The analysis of variations within ICOS gene as well as its expression profile in the patients with autoimmune disorders will be of interest.
Another major new finding of this study is the presence of four alleles in the 5′-flanking region of CD80. Interestingly, all four alleles have been maintained at high frequencies. Surprisingly, A −454 -T −387 -A −232 -C −79 -C −7 -A 5 allele, which carries at least four nucleotide substitutions compared with other alleles as well as a five-nucleotide insertion, is also present in a considerable proportion of the Japanese population. These observations suggest that the polymorphism within the 5′-flanking region of CD80 may have been maintained by balancing selection, and further studies in other human populations will be of particular interest to gain more insight into the evolutionary pathway of these alleles. The relationship between transcriptional activity and these variations is at this point unclear. The observed nucleotide substitutions do not create new binding motifs for known transcription factors, but substitution of C for T at position −7 disrupts AP-1 binding motif 40 (TFSEACH; http://pdap1.trc.rwcp.or.jp/research/db/ TFSEARCH.html 41 ). Further analysis will be of interest to test functional significance of the variation within the 5′-flanking region of CD80 gene, as well as its possible association with the susceptibility to other autoimmune disorders, such as allergic diseases.
Materials and methods

Patients and healthy individuals
A total of 149 patients with RA, 77 patients with SLE and 270 healthy individuals were examined in a retrospective manner. All patients and healthy individuals were unrelated Japanese. Patients with RA were followed in the outpatient clinic of University of Tokyo Hospital or Fukuhara Hospital (Tokyo), and fulfilled the classification criteria of American College of Rheumatology. 42 Patients with SLE were followed in the outpatient clinic of UniGenes and Immunity versity of Tokyo Hospital or Matsuta clinic (Tokyo) and fulfilled the classification criteria of American College of Rheumatology. 43 Healthy individuals consisted of the researchers or laboratory workers at Japan Red Cross Central Blood Center, Japan Red Cross Kanagawa Blood Center, Wakunaga Pharmaceutical company, and graduate students at the University of Tokyo. All examined individuals were unrelated Japanese living in Tokyo area, the central part of Japan. The area has been shown to be homogeneous with respect to genetic background, 44 permitting the case-control approach employed in this study. This study was reviewed and approved by the Ethics Committee of the University of Tokyo, Graduate School of Medicine.
Genomic DNA
Genomic DNA from patients and healthy individuals was purified from peripheral blood leukocytes using QIAmp blood kit (Qiagen, Hilden, Germany).
PCR amplification of CD80 and CD86
Human CD80 gene is located at 3q21 and consists of 6 exons, among which exons 2 through 6 correspond to the coding region. 30, 36 Human CD86 gene is also located at 3q21 36 and consists of 8 exons, among which exons 3 through 8 correspond to the coding region. 32 Each exon of CD80 or CD86 was amplified using the specific primer sets designed within flanking introns. The sequences of the primers used in this study were listed in Table 6 . Exons 3 and 4 of CD80 and exons 4 and 5 of CD86 were divided into two regions because of the appropriate size for PCR-PHFA. The reverse primers for CD80 exon 6 and CD86 exon 8 were placed within the 3′-UTR. Amplifications were performed using 20 ෂ 100 ng genomic DNA, 1U Taq polymerase (AmpliTaq Gold™, PE Applied Biosystems, Foster City, CA, USA), 1 × PCR buffer II (PE Applied Biosystems), 2.5 mm MgCl 2 , 10 pmol of each primer, and 0.2 mm dNTP mixture in 25 l reaction. The amplification procedure consisted of initial denaturation at 96°C for 10 min, 35 cycles of denaturation (96°C, 30 s), annealing (30 s), and extension (72°C, 1 min) . The doublelabeled amplicon was prepared with biotin-labeled forward primer and DNP-labeled reverse primer. The unlabeled amplicon was prepared with unlabeled primers. The amplicons were used for hybridization without purification. Preparation of the standard DNA for polymorphism screening Each exon fragment was amplified with unlabeled primer set and then cloned using TA cloning Kit (Invitrogen, Carlsbad, CA, USA). The nucleotide sequences of the cloned fragments were confirmed by DNA sequencing. The standard DNA for variation screening was prepared using unlabeled primer set using the cloned fragment as a template.
Polymorphism screening using PHFA PHFA is an ELISA-based method for the simple and reliable detection of single base substitutions within PCR amplicons, based on the strand competition during hybridization between double-labeled and unlabeled amplicons under the precisely controlled temperature gradient. 45 Variation screening using PCR-PHFA was described previously. 27 Briefly, hybridization was performed in 30 l of 5 × SSC in the PCR tube, containing 0.5 l of the sample product and 1.5 l of standard DNA. For hybridization under the temperature gradient, the reaction mixtures were denatured at 98°C for 10 min, then slowly cooled to 88°C at the rate of 1°C per 20 min using the thermal cycler. Subsequently, 20 l of reaction mixture was transferred to a streptavidin-coated microtiter plate (Wakunaga, Hiroshima, Japan) containing anti-DNP antibody conjugated with alkaline phosphatase (Wakunaga), then the color development procedure was performed as previously described.
27
Polymorphism screening by DNA sequencing CD28 gene and the promoter region of CD80 were screened for variations in 10 healthy individuals, 10 patients with RA and 10 patients with SLE by direct sequencing. Human CD28 gene is located at 2q33-34 20 and consists of 4 exons. 46 Each exon of CD28 was amplified using the specific primer set designed within flanking introns. The amplified fragment of exon 4 included the coding sequence and 5′-portion of 3′-UTR. The promoter element of CD80 gene has been identified. 40, 47 A 690 bp fragment of 5′-flanking region of CD80 gene (−637 ෂ +53, promoter-full) was amplified. PCR amplicon was purified using the cartridge filter (Suprec-02, Takara, Kyoto, Japan) before sequencing reaction. Primers used in the sequencing reaction were the same as those used for the amplification. In the sequencing of CD80 promoter region, two sequencing reactions were performed for each strand using the additional primers, 5′-CAGAAA CAGCCAGCCCATGA-3′ for sense strand and 5′-TTAGCACCCAGAGTTACTCC-3′ for antisense strand designed within the amplified promoter region. DNA sequencing was carried out by the dideoxy chain termination method using a commercially available kit (dRhodamine dye Terminator Cycle Sequencing FS Ready Reaction Kit, PE Applied Biosystems) and an automated DNA sequencer (ABI PRISM 377, PE Applied Biosystems). For the genotyping of detected variations, the CD80 promoter region was separated into two fragments (upstream and downstream), and were amplified ( Table 6 ).
Genotyping of CD80 downstream promoter region using PCR-PHFA PCR-PHFA has been successfully applied to the allele typing for HLA-DPB1, 45 human platelet antigens (HPAs), 48 and Fc␥RIIIB, 24 and we have recently established the allele typing method of human TNFA 5′-flanking region using PCR-PHFA. 49 The downstream promoter regions of the genomic DNA from three samples possessing (−79C/C, −7T/T, +5C/C), (−79G/G, −7T/T, +5C/C) and (−79C/C, −7C/C, +5A/A) genotypes, respectively, were amplified using biotin-labeled forward primer and DNP-labeled reverse primer and were used as the standard DNAs. Using these standard DNAs, 30 directly sequenced samples were genotyped by PFHA. All genotypes were consistent with those deduced from sequencing results (data not shown), indicating that the PCR-PHFA method can be used for the genotyping of CD80 downstream promoter region.
Genotyping of exon 3-1 fragment of CD80, exon 8 of CD86 and upstream promoter fragment of CD80 using PCR-SSCP The genotypes of CD80 exon 3-1, CD86 exon 8 and CD80 upstream promoter fragments were analyzed by PCR-SSCP, as described previously. 21 Briefly, 1 l of PCR amplicons was mixed with 7 l loading solution (95% formamide, 20 mm EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol), incubated for 5 min at 96°C, and loaded onto an 10% polyacrylamide gel without glycerol. Gel electrophoresis was carried out at 20 mA at a constant temperature of 10°C. The running time of electrophoresis was 90 min for exon 3-1 fragment of CD80 and exon 8 of CD86, 70 min for upstream promoter fragment of CD80. The bands were visualized using silver stain kit 'DAIICHI' (Daiichi Pure Chemicals, Tokyo, Japan).
Statistical analysis
Carrier rate of the variant allele was defined as the percentage of individuals possessing at least one variant allele.
2 test was used to analyze the association of SNPs identified in this study with susceptibility to RA and SLE. Fisher's exact test was used when the sample number was small.
